News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Mark A. Socinski, MD, AdventHealth Cancer Institute

Articles by Mark A. Socinski, MD, AdventHealth Cancer Institute

Challenges for TRK Fusion–Targeting Agents

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Acquired Resistance in TRK Fusion-Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Approaching Treatment for TRK Fusion–Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

TRK Inhibitor in GI Cancers: Adverse Effect Profile

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Efficacy of TRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Early Development of TRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Advice for Interpreting NGS Reports

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Driver Mutations in NTRK Fusion-Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Genomic Testing for NTRK Fusions in Lung and GI Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Approaching Genomic Testing for NTRK Fusions

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Using Molecular Testing in GI Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Evolution of NGS Testing in Lung Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Variants of NTRK Fusions in Solid Tumors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Role of NTRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma